MUCOCIS OS GRAT 30BUST5G 300MG

MUCOCIS 300 MG FREE FOR ORAL SOSPENSION

active ingredients

MUCOCIS 0.3 g granulate for oral suspension A 5 gram granulate envelope contains: Active Principle: carbocysteine 0.3g Excipient: sucrose For the full list of excipients, see paragraph 6.1.

Excellent

Sodium bicarbonate, citric acid, colloidal silica, orange aroma, lemon aroma, sucrose.

Therapeutic indications

Mucolitic and fluidifying in the acute and chronic affections of the respiratory system.

Contraindications

Hypersensitivity to the active ingredient or any of the excipients listed in paragraph 6.1. Gastro-duodenal ulcers. Pregnancy and nursing (see paragraph 4.6). The drug is contraindicated in children under 2 years of age.

Population

Adults: 1 bag 3-4 times a day. Children: 1/2-1 sachet 2 times a day. Dissolve the recommended doses in a glass containing two fingers of water, stirring with a teaspoon.

Conservation

Store at room temperature.

Warnings

Mucolitics may induce bronchial obstruction in children under 2 years of age. In fact the drainage capacity of the bronchial mucus is limited in this age range, due to the physiological characteristics of the respiratory tract. They must not be used in children under 2 years of age (see paragraph 4.3) The product contains sucrose: keep in mind in case of diabetes or hypocaloric diets. Patients with rare hereditary problems of fructose intolerance, glucose-galactosis mal absorption, or isomaltase sucrasis failure, should not take this medicine. The product contains para-hydroxybenzoate methyl, p-hydroxybenzoate ethyl, p-hydroxybenzoate propile, which can cause allergic reactions, generally delayed. Gastrointestinal bleeding: Cases of gastrointestinal bleeding were reported with the use of carbocysteine. It is recommended caution in the elderly, in patients with a history of gastrointestinal ulcers or in patients taking concomitant drugs known to increase the risk of gastrointestinal bleeding. In case of gastrointestinal bleeding, the patient must stop treatment with carboxysteine. Asthmatic and debilitated patients: It is recommended to take specific precautions in patients with severe respiratory failure, in patients with asthma and with a history of bronchospasm, as well as in debilitated patients. The use of carboxysteine causes a decrease in the viscosity of the mucus and an increase in the removal of the mucus, both through the ciliar activity of the epithelium, and through the reflex of the cough. Therefore, there is an increase in cough and inspectorate. The use of antitussive medicines inhibits cough reflex and increases the risk of airway obstruction, due to an increase in mucus accumulation in respiratory tract. Concurrent use of this medicine with sedative medications of cough and/or medicines that inhibit bronchial secretion (e.g. antimuscarinic medicines) is not recommended.

Interactions

At present they are not known.

Effects

The side effects are listed according to the following frequency classification: Very common (≥ 1/10); common (≥ 1/100, Classification for systems and organs according to MedDRA Very common Town Not common Rare Very rare Notable Immune system disorders           Anaphylactic reaction, fixed erythema from medication, allergic skin rash Gastrointestinal diseases Diarrhea, nausea and superior abdominal pain         Epigastric fastidium, vomiting and gastrointestinal bleeding Pathologies of skin and subcutaneous tissue           Steven-Johnson syndrome, bullying dermatitis, multiform erythema, toxic rash, skin rash Respiratory, chest and mediastinic pathologies           Bronchial obstruction Ear and labyrinth pathologies           Vertigo Reporting of suspicious adverse reactions The reporting of suspicious adverse reactions that occur after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare workers are required to report any suspected adverse reaction via the national reporting system at the address www.aifa.gov.it/content/segnalazioni-reazioni-avverse.

Overdosing

Symptoms due to overdose include: headaches, nausea, diarrhea, gastralgia. In case of overdose cause vomiting and possibly practice gastric lavender.

Although the active ingredient is neither teratogenic nor mutagenic and has not shown any adverse effects on the reproductive function in the animal, data on its use in human pregnancy are not available. Therefore the use of the medicinal product is contraindicated in pregnancy. Since there is no data on the passage of carboxysteine in breast milk, the use of the medicinal product is contraindicated during breastfeeding.

Source: Farmadati